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Abstract
Background: Sarcosine, a glycine transporter type 1 inhibitor and an N-methyl-D-aspartate (NMDA) receptor
co-agonist at the glycine binding site, potentiates NMDA receptor function. Structurally similar to sarcosine,
N,N-dimethylglycine (DMG) is also N-methyl glycine-derivative amino acid and commonly used as a dietary
supplement. The present study compared the effects of sarcosine and DMG on NMDA receptor-mediated
excitatory field potentials (EFPs) in mouse medial prefrontal cortex brain slices using a multi-electrode array
system.
Results: Glycine, sarcosine and DMG alone did not alter the NMDA receptor-mediated EFPs, but in combination
with glutamate, glycine and its N-methyl derivatives significantly increased the frequency and amplitude of EFPs.
The enhancing effects of glycine analogs in combination with glutamate on EFPs were remarkably reduced by the
glycine binding site antagonist 7-chlorokynurenate (7-CK). However, DMG, but not sarcosine, reduced the frequency
and amplitude of EFPs elicited by co-application of glutamate plus glycine. D-cycloserine, a partial agonist at the
glycine binding site on NMDA receptors, affected EFPs in a similar manner to DMG. Furthermore, DMG, but not
sarcosine, reduced the frequencies and amplitudes of EFPs elicited by glutamate plus D-serine, another endogenous
ligand for glycine binding site.
Conclusions: These findings suggest that sarcosine acts as a full agonist, yet DMG is a partial agonist at glycine
binding site of NMDA receptors. The molecular docking analysis indicated that the interactions of glycine, sarcosine,
and DMG to NMDA receptors are highly similar, supporting that the glycine binding site of NMDA receptors is a critical
target site for sarcosine and DMG.
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Background
Derivatives of glycine, including N-methylglycine (sarco-
sine) and N, N-dimethylglycine (DMG) are important
intermediates in the metabolism of choline to glycine
[30, 40]. Sarcosine and DMG are widely distributed in
food and used as dietary supplements. These two struc-
turally similar glycine derivatives were reported to have
pharmacological activities in the central nervous system.
Sarcosine is a competitive glycine transporter type-l
inhibitor [16], an N-methyl-D-aspartic acid (NMDA) re-
ceptor co-agonist [45], and a glycine receptor agonist
[46]. Based on its enhancing effects on NMDA receptors,
sarcosine has been studied for its efficacy in ameliorating
negative and cognitive symptoms in patients with schizo-
phrenia, showing promising results [18, 21, 33, 35]. In
addition, sarcosine can improve depression-like behaviors
in rodent models and in human depression [18]. The
toluene-induced behavioral aberrations were also attenu-
ated by sarcosine [4].
DMG, consisting of one more methyl group than
sarcosine, has been reported to decrease oxidative stress
[36], to improve immune responses [15] and to be pro-
moted as an athletic performance enhancer [34]. DMG
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also acts on central nervous system since it exhibits anti-
convulsant activity in animal models [11]. Recently, it
has been reported that DMG has antidepressant-like ef-
fect and reduces the ketamine-induced psychotomimetic
behaviors in mice [24]. Furthermore, DMG has been
tested as a supplement for patients with autism or per-
vasive developmental disorder [1, 3, 19, 43], although
the results from these clinical studies are controversial.
Opening of the NMDA receptor channel complex re-
quires occupation of its glutamate binding site by glu-
tamate and its glycine binding site by glycine or D-serine
[41]. Thus, glycine is not only a glycine receptor agonist,
but also a co-agonist of NMDA receptors. In addition to
inhibiting the glycine transporter 1 and increasing the am-
bient glycine concentration, sarcosine, simply the glycine
molecule with one methyl group added, also directly acts
on NMDA receptors [45]. However, it remains unknown
whether DMG, with two methyl groups added to glycine,
has the capacity to modulate NMDA receptors.
As enhancement of NMDA receptor function (directly
or indirectly) has been associated with the therapeutic po-
tential of sarcosine for psychiatric disorders, the present
study aimed to compare the effects of srcosine and DMG
on NMDA receptor function. A multi-electrode array sys-
tem was used to measure the NMDA receptor-mediated
excitatory field potentials (EFPs) in slice preparations of
mouse medial prefrontal cortex because medial prefrontal
cortex has been implicated in the processing of a wide
range of cognitive and emotional stimuli and is thought to
function as a central hub in the brain circuitry mediating
symptoms of psychiatric disorders [31].
In our preparations, with TTX, bicuculline, and in the
absence of magnesium ion, the electrophysiological sig-
nals are generated by the summed electric current flow-
ing from NMDA receptors in the neurons in the vicinity
of the electrode. The frequency of EFPs reflects the open
probability of NMDA receptors. The amplitude of field
potentials arises from the synchronization of neural ac-
tivity. In this case the amplitude is representative of the
amounts of NMDA receptors are activated simultan-
eously. When the open probability of the channels in
the neurons is dramatically increased, the number of
channels opened at the same time will be increased
accordingly.
The roles of sarcosine and DMG on NMDA receptor-
mediated EFPs were determined by their co-application
with glutamate in the absence or presence of endogenous
co-agonists glycine. The manifestation of D-cycloserine, a
well-known partial agonist at the glycine binding site on
NMDA receptors, in the same experimental preparation
was illustrated for comparison. In addition, their effects
on NMDA receptor-mediated EFPs evoked by glutamate
plus D-serine, another endogenous co-agonist for the gly-
cine site of the synaptic NMDA receptors, were assessed.
Finally, the molecular docking simulations were used to
evaluate the possible binding between NMDA receptor




Male ICR mice (8–10 weeks) were supplied from
BioLASCO (Taiwan) and housed 4 to 5 per cage in a
12 h light/dark cycle (lights on 0700 h) with ad libitum
access to water and food during the time the animals
were in their home cages. All experiments were per-
formed in accordance with the Republic of China animal
protection law (Chapter III: Scientific Application of
Animals) and approved by Institutional Animal Care
and Use Committee of the National Health Research
Institutes (NHRI-IACUC-10430-A).
Glycine and potassium chloride were purchased from
J.T. Baker (Mallinckrodt Baker, Inc, Kentucky, USA).
Sarcosine, DMG, ketamine, and 7-chlorokynurenic acid
(7-CK) and other chemicals were obtained from Sigma
(St Louis, MO, USA). The individual reagents were
dissolved in an artificial cerebrospinalfluid (ACSF) con-
taining (in mM) NaCl (120), KCl (3.5), CaCl2 (2.5),
MgCl2 (1.2), NaHCO3 [24], NaH2PO4 (1.2), and D-
glucose (11.5) at pH 7.4.
Preparation of prefrontal cortex (PFC) slices for
electrophysiological recordings
The brains of ICR mice were removed and immersed in
an ice-cold ACSF, bubbled with a mixture of 95% O2/5%
CO2. Coronal slices (300 μm) were cut from the frontal
cortex (3–5.16 mm anterior to bregma) using a vibrating
tissue slicer. After recovery for at least 1 h at room
temperature, a single slice was transferred to the center
area of the coated MED probe (Panasonic, Japan) and
positioned to cover the 8 × 8 microelectrode array by a
paint brush. The positioned slice was superfused at
2.0 ml/min with ACSF saturated with O2.
Electrophysiological recordings
For electrophysiological recordings, the MED probe con-
taining the brain slice was placed in a small incubator
which was superfused with Mg2+ free-ACSF in 5% CO2/
95% O2 at 25 °C and connected to the stimulation/re-
cording component of MED8 multi-electrode array sys-
tem (Panasonic, Japan). Mg2+-free ACSF was used to
minimize Mg2+ block of NMDA receptors. The prepar-
ation of the multi-electrode dish has been described pre-
viously [6]. Briefly, the MED probe is an array of 64
planar microelectrodes, where each microelectrode has a
size of 50 × 50 μm and is arranged in an 8 × 8 pattern.
The interpolar distance in this type of probe (MED-
P515A) is 150 μm. For sufficient adhesion of the brain
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slice to the MED probe, the surface of probe was treated
with 0.1% polyethylenimine in 25 mM borate buffer for
8 h at room temperature. Then the probe surface was
rinsed three times with distilled water for future
experiments.
The field potentials at 8 sites in the 64 multi-electrode
probe were recorded simultaneously with the multi-
channel recording system at a 20 kHz sampling rate.
The electrodes in the infralimbic prefrontal cortex were
selected as the recording electrodes. In order to prevent
the sodium channel-mediated action potential activity
and the interference of inhibitory field potentials, all the
experiments were performed with tetrodotoxin (TTX)
(300 nM) and bicuculine (10 uM). The recording of spon-
taneous excitatory field potentials (EFPs) in the presence
of TTX and bicuculline was first carried out to establish a
stable baseline. The changes in the amplitude and fre-
quency of NMDA receptor-mediated EFPs evoked by vari-
ous ligands, which were continuously applied by adding
them into the bath medium, were expressed as percent-
ages of baseline, which were set at 100%.
Statistical analyses
The frequency and amplitude (>0.2 mV) of field potentials
were measured. All data are expressed as mean ± S.E.M.
Statistical significance of the difference between
groups was determined by one-way or two-way re-
peated measures ANOVA followed by a Student-
Newman-Keuls post-hoc test. p < 0.05 was considered
statistically significant.
Molecular docking analysis
Glycine, sarcosine, and DMG were docked with the
NMDA receptor NR1 ligand-binding core (PDB ID:
1PB7) [14] using Glide XP 6.5 [12, 13] from the program
in Schrödinger (Schrödinger Suite 2014-4, Schrödinger,
LLC, New York, NY, USA, 2014). The missing side chain
atoms were built by using Dunbrack rotamer library [9] in
UCSF Chimera (Version 1.6.2. [28], UC San Francisco, San
Francisco, CA, USA, 2012). The water molecules beyond
5 Å of the crystallized glycine were removed. The 3D con-
formations and protonized states of ligands were generated
using LigPrep 3.2 from Schrödinger (Schrödinger Suite
2014-4, Schrödinger, LLC, New York, NY, USA, 2014).
The docking box was a cubic box with sides of 17.51 Å
long, which centered as the crystalized glycine. To test
whether the docking system is feasible for the ligand bind-
ing to NMDA receptor, the NMDA-NR1-Glycine complex
(PDB ID 1PB7) was initially selected while glycine was
redocked back to the complex. The docking structure of
glycine was compared to its original crystallographic gly-
cine structure. The root-mean-square distance (RMSD)
between these two poses was only 1.49 Å. This result im-
plied that the Glide docking program and docking settings
used is suitable for the evaluating the possible binding be-
tween NMDA receptor NR1 and ligands of interests, gly-
cine, sarcosine, and DMG.
Results
Characterization of NMDA receptor-mediated excitatory
field potentials (EFPs)
Figure 1 illustrates the experimental protocol and repre-
sentative recordings of field potentials in the prefrontal
cortical slices of mouse brains. The baseline of EFPs in an
individual prefrontal cortical slice was initially recorded for
5–10 min in the presence of TTX and bicuculline. The glu-
tamate (100 μM) and glycine (10 μM) alone, and then glu-
tamate (100 μM) plus glycine (10 μM) was applied to
stimulate the field potentials, followed by co-application of
glutamate (100 μM) plus glycine (10 μM) with the selective
NMDA receptor antagonists ketamine or D-2-amino-5-
phosphonopentanoate (D-AP5), the competitive NMDA
receptor glycine site antagonist 7-chlorokynurenic acid (7-
CK), or 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), a
competitive AMPA/kainate receptor antagonist. The
baseline activity of EFPs was of low voltage under TTX
treatment and the activity of inhibitory field potentials
in the mouse medial prefrontal cortex was blocked in
the presence of bicuculline. Perfusion of glutamate or
glycine alone into the slices did not produce more EFPs
than baseline, whereas co-application of glutamate
(100 μM) and glycine (10 μM) significantly evoked field
potentials. The frequency and amplitude of glutamate
plus glycine-evoked EFPs were blocked by the NMDA
receptor antagonists, ketamine and D-AP5, and the gly-
cine binding site antagonist 7-CK, but not by AMPA/
kainate receptor antagonist CNQX. These results re-
vealed that EFPs evoked by glutamate plus glycine were
mediated by NMDA receptors.
Effects of sarcosine and DMG alone or combined with
glutamate on excitatory field potentials
To test if DMG, like sarcosine, acts as NMDA receptor
glycine binding site co-agonists, the concentration-
dependent effects of these three glycine-derivatives on
excitatory field potentials were examined in two condi-
tions which are sarcosine, or DMG alone or combined
with glutamate (100 μM). In each brain slice glutamate
(100 μM), glycine (10 μM), and glutamate plus glycine
were sequentially applied as positive controls followed
by one of N-methyl glycine derivatives in the absence
and presence of glutamate (Fig. 2a). Sarcosine or DMG
(100 μM) alone had no effect on EFPs similar to glycine
alone (Fig. 2b-c). Co-application of sarcosine or DMG
(10, 30, and 100 μM) with glutamate resulted in
concentration-dependent enhancement of the frequency
and amplitude of the excitatory field potentials (Fig. 2).
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Effects of sarcosine and DMG on glutamate/glycine-evoked
excitatory field potentials
Experimental protocol was illustrated in Fig. 3a. Vari-
ous concentrations (10, 30 and 100 μM) of sarcosine
and DMG were sequentially applied in the presence of
glutamate plus glycine after glutamate (100 μM), gly-
cine (10 μM), and glutamate plus glycine. Both the fre-
quency and amplitude of NMDA receptor-mediated
EFPs were significantly attenuated by high concentra-
tion (100 μM) of DMG, but not affected by sarcosine
(Fig. 3b, c). These observations suggest that sarcosine is
a co-agonist, in line with previous reports, whereas
DMG acts more like a partial agonist at glycine binding
site of NMDA receptors.
Effects of D-cycloserine on NMDA receptor-mediated
excitatory field potentials
This experiment was designed to reveal if D-cycloserine,
a well-known partial agonist at the glycine binding site
on NMDA receptors, produces similar effects on NMDA
receptor-mediated EFPs as DMG. The protocol and rep-
resentative recordings were shown in Fig. 4a and b. D-
cycloserine alone did not evoke EFPs. The frequency
and amplitude of EFPs were significantly increased by
co-application of D-cycloserine at 30 μM, but not
10 μM, with glutamate. However, the frequency and
amplitude of glutamate plus glycine-evoked EFPs were
attenuated by D-cycloserine (30 μM).
Effects of 7-CK on excitatory field potentials evoked by
co-application of glutamate with sarcosine, DMG and
D-cycloserine
The inhibitory effects of 7-CK, a selective antagonist at
glycine binding site of NMDA receptors, on EFPs
evoked by co-application of glutamate with sarcosine,
DMG and D-cycloserine were assessed. As shown as
previous experiments, co-application of glutamate with
sarcosine (100 μM), DMG (100 μM) and D-cycloserine
(30 μM) significantly increased the frequency and ampli-
tude of EFPs. Their enhancing effects were abolished by
7-CK (Fig. 5).
Effects of sarcosine and DMG on glutamate plus
D-serine-evoked excitatory field potentials
Glycine is a two-faceted bioactive molecule in the cen-
tral nervous system [44]. In addition to being essential
for the activation of NMDA receptor function, glycine is
one of the main inhibitory neurotransmitters acting on
glycine receptors. The simultaneous activation of excita-
tory NMDA receptors and inhibitory glycine receptors
may interfere with the generation of excitatory field po-
tentials. Therefore, the interactions between glycine me-
thyl derivatives and D-serine, a selective and potent
endogenous agonist for the glycine binding site of the
NMDA receptors, were explored. This experiment ex-
amined the effects of sarcosine, DMG and D-cycloserine
on the EFPs evoked by co-application of glutamate and
D-serine. As shown in Fig. 6, D-serine alone did not
Fig. 1 Characterization of NMDA receptor-mediated excitatory field potentials. The experimental protocol (a) and the representative field potential
recordings (b) of excitatory filed potentials in an individual prefrontal cortical slice in the presence of TTX (0.3 μM) and bicuculline (10 μM) were
shown after the application of glutamate (100 μM) and glycine (10 μM) alone, and then glutamate plus glycine, followed by co-application of
glutamate (100 μM) plus glycine (10 μM) with ketamine (10 μM), 7-CK (1 μM), CNQX (10 μM) or D-AP5 (100 μM)
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affect the field potentials, whereas co-application of glu-
tamate and D-serine evoked excitatory field potentials.
The frequency and amplitude of glutamate plus D-
serine-induced EFPs were significantly reduced by DMG
(100 μM) and D-cycloserine (30 μM), but not sarcosine
(100 μM).
Molecular docking of glycine, sarcosine and DMG with
NMDA receptors
To gain insight into the molecular interaction between
glycine, sarcosine and DMG with the glycine binding site
of NMDA receptor, molecular docking simulations for
glycine, sarcosine, and DMG to NMDA receptor NR1
ligand-binding core (PDB ID: 1PB7) [14] were performed
using Glide based on the X-ray cocrystal structure of
NMDA receptor NR1 ligand-binding core with glycine
as a co-crystalized ligand (PDB ID 1PB7). As shown in
Fig. 7a (glycine), Fig. 7b (sarcosine), and Fig. 7c (DMG),
the potential hydrogen bonds were the same: 4 hydrogen
bonds which oxygen atoms at the carboxylic group were
the acceptors, and the amine group as the hydrogen
donor. Each oxygen atom at carboxylic group was a
hydrogen bond acceptor of different guanidinium nitro-
gen atom of ARG523. Also, one oxygen atom was also
the hydrogen bond donor of the main chain nitrogen
atom of SER688. The other oxygen atom was also the
hydrogen bond donor of the main chain nitrogen of
THR518. Moreover, the nitrogen atom at amine group
was the hydrogen donor of the side chain oxygen of
ASP732. These 5 potential hydrogen bonds were the
main interaction between these ligands and the binding
site of NMDA receptor NR1, which were also indicated
in the study of crystal structure [14]. Moreover, the ni-
trogen atom at amino group might form cation-pi inter-
action with PHE484 (glycine, sarcosine, and DMG) and
TRP731 (glycine and sarcosine only).
Fig. 2 Effects of sarcosine and DMG alone or combined with glutamate on excitatory field potentials. The effects of glutamate (100 μM), glycine
(10 μM), and glutamate plus glycine were examined prior to the glycine methyl derivatives to verify the slice activity. The experimental protocol
(a), the representative field potential recordings (b), and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials
after perfusion with sarcosine or DMG (100 μM) alone and various concentrations of sarcosine (c) or DMG (d) (10, 30, and 100 μM) plus
glutamate (100 μM). (Frequency: sarcosine F7,21 = 29.43, p < 0.001; DMG F7,21 = 48.94, p < 0.001; Amplitude: sarcosine F7,21 = 28.17, p < 0.001;
DMG F7,21 = 5.28, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM (n = 4). ***p < 0.001 compared with baseline
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Comparing these results, the interactions of glycine,
sarcosine, and DMG to NMDA receptor were highly
similar. However, the number of methyl groups bound
to the amine group affected the binding affinity due to
the hydrogen bonds and the nitrogen atom at the amine
group which matched to our findings through EFPs.
Discussion
The present study compared the effects of sarcosine and
DMG on NMDA receptor–mediated EFPs in the mouse
prefrontal cortical slices. Sarcosine and DMG alone, like
endogenous co-agonists glycine and D-serine, did not
change the EFPs and significantly enhanced the fre-
quency and amplitude of EFPs in the presence of glu-
tamate. The enhancing effects of glycine, sarcosine and
DMG were blocked by the competitive NMDA receptor
glycine binding site antagonist 7-CK, suggesting these
two N-methyl glycine derivatives might act on the gly-
cine binding site. From the results of molecular docking
analysis, the binding modes of glycine, sarcosine, and
DMG were similar, supporting that the glycine binding
site is their target site. However, DMG, but not sarco-
sine, at higher concentration (100 μM) reduced EFPs in
the presence of glutamate plus glycine/D-serine
(10 μM) and the inhibitory effect of DMG could be at-
tenuated by elevated glycine concentration (100 μM)
(Additional file 1: Figure S1). Furthermore, under the
same experimental procedure, the pattern of responses
to D-cycloserine, a well known NMDA receptor glycine
site partial agonist [22, 39], was similar to DMG. These
results reveal that sarcosine is an agonist, whereas
DMG acts more like a partial agonist at glycine binding
site of the NMDA receptors.
Glutamate, glycine, D-serine, sarcosine, or DMG alone
did not change EFPs and co-application of glutamate or
NMDA (Additional file 2: Figure S2) with glycine, D-
serine, or N-methyl glycine derivatives significantly in-
creased the frequency and amplitude of EFPs. These
results support the notion that occupancy of both glutam-
ate and glycine binding sites is necessary for NMDA
Fig. 3 Effects of sarcosine or DMG on glutamate/glycine-evoked excitatory field potentials. The experimental protocol (a), the representative field
potential recordings (b), and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials (c) after application of glutamate,
glycine, glutamate (100 μM) plus glycine (10 μM) and various concentrations (10, 30 and 100 μM) of sarcosine and DMG sequentially with glutamate
plus glycine. The data were analyzed by one-way repeated measures ANOVA (Frequency: F9,27 = 50.58, p < 0.001; Amplitude: F9,27 = 54.64, p < 0.001).
Data are expressed as percentage of baseline, mean ± SEM (n = 4). ***p < 0.001 compared with baseline. ###p < 0.001 compared with glutamate
plus glycine
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receptor activation. Moreover, the glutamate and glycine
binding sites of NMDA receptors are scarcely occupied in
the presence of TTX in acute slice preparations of medial
prefrontal cortex and the NMDA receptor-mediated re-
sponse observed here is independent of glutamate release.
Sarcosine enhanced EFPs with glutamate, but did not
affect the glutamate plus glycine/D-serine-evoked EFPs.
These results are consistent with previous findings that
sarcosine enhances NMDA receptor function by dir-
ectly acting as a co-agonist [45] or indirectly inhibiting
the glycine transporter to increase glycine availability
[17, 25]. It has been reported that sarcosine is less po-
tent than glycine at NMDA receptor-mediated currents
using whole-cell voltage clamp recordings from cul-
tured embryonic mouse hippocampal neurons [45]. In
the same manner, our data showed that in the presence
of glutamate, sarcosine (100 μM) produced EFPs to the
same extent as glycine (10 μM) in the prefrontal cor-
tical slices, supporting the lower potency of sarcosine
than glycine. The molecular docking analysis demon-
strated that the binding modes of glycine, sarcosine and
DMG are very similar. Moreover, the number of methyl
groups bound to the amine group, which was the main
difference between ligands, would affect the role of the
nitrogen atom as the hydrogen bond donor and the
binding affinity to the glycine binding site. However,
the potencies of sarcosine and DMG to co-activate
EFPs with glutamate in the brain slice preparations
were approximately equal. It is possible that in addition
to their direct interaction with NR1 subunit, there are
some other factors and certain indirect effects of sarco-
sine and DMG contributing to their potencies to evoke
EFPs with glutamate. To further elucidate the role of
DMG in NMDA receptor function, it would be import-
ant to measure the whole-cell NMDA receptor-
mediated synaptic currents or potential using whole-
cell patch-clamp recordings.
NMDA receptors are ligand-gated ion channels assem-
bled from NR1 and NR2 subunits. Although the glycine
binding site is located in NR1 subunit, the potencies [7]
and efficacies [8] of glycine binding site agonists are
dependent on the NR2 subunit. In fact, NR2A- and
Fig. 4 Effects of D-cycloserine on NMDA receptor-mediated excitatory field potentials. The experimental protocol (a), the representative field
potential recordings (b), and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials (c) after the application
D-cycloserine alone, co-application of D-cycloserine (10 and 30 μM) with glutamate or glutamate plus glycine. The data were analyzed by
one-way repeated measures ANOVA (Frequency: F8,24 = 70.25, p < 0.001; Amplitude: F8,24 = 100.8, p < 0.001). Data are expressed as percentage of
baseline, mean ± SEM (n = 4). ***p < 0.001 compared with baseline. ###p < 0.001 compared with glutamate plus glycine. DCS:D-cycloserine
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NR2B-containing NMDA receptors are predominantly
expressed in the medial prefrontal cortex [38]. Our ob-
servations in the infralimbic cortex might only reflect
the effects of these N-methyl glycine derivatives on
NR2A- together with NR2B-containing NMDA receptors.
It remains to be investigated whether these N-methyl gly-
cine derivatives affect NR2C- or NR2D-containing NMDA
receptors in the same manner and the NR3-containing
NMDA receptors that respond to glycine agonists alone
[29] can be activated by N-methyl glycine derivatives
directly. A study for elucidating the differential effects of
these glycine analogs on NMDA receptors containing
distinct types of NR2 subunits is in progress.
Modulation of NMDA receptor glycine binding site
has been proposed as the next wave of drug develop-
ment for schizophrenia [5], depression [10], and autism
spectrum disorders [32]. It is generally believed that
the augmentation of NMDA receptor transmission can
improve the negative and cognitive symptoms in
schizophrenia. In fact, sarcosine, when added to an
existing regimen of antipsychotic drugs, has shown its
efficacy for both chronically stable and acutely ill
patients [18, 20, 37]. Therefore, it is postulated that
NMDA receptors at key synapses are not saturated
with glycine in schizophrenic patients and administra-
tion of these glycine derivatives is capable of enhancing
NMDA receptor function by increasing agonist occu-
pancy at the glycine binding site. Since DMG can be
metabolized to sarcosine, it is of interest to determine
if their clinical potency is higher than sarcosine in the
treatment of schizophrenia.
Sarcosine can improve depression-like behaviors in ro-
dent models and in human depression [18]. However, it
may be not like NMDAR antagonist ketamine with rapid
onset and sustained antidepressant effect. In fact, a glycine
binding site partial agonist GLYX-13 has been reported to
have long-lasting antidepressant-like effects in preclinical
study and is currently in clinical trials as an add-on to
already approved treatments for treatment-resistant de-
pression patients [2, 26]. Similarly, DMG showed persist-
ent antidepressant-like effects in mice [24].
DMG has been used as a nutritional supplement for aut-
istic spectrum disorders and there is anecdotal evidence
from parents, medical professionals, and caretakers
Fig. 5 Effects of 7-CK on excitatory field potentials evoked by co-application of glutamate with sarcosine, DMG and D-cycloserine. The experimental
protocol (a) and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials (b) after the application of sarcosine (100 μM),
DMG (100 μM), and D-cycloserine (30 μM) plus glutamate with or without 7-CK (1 μM). Two-way repeated measures ANOVA demonstrated significant
effects of 7-CK (Frequency: F1,9 = 645.38, p < 0.001; Amplitude: F1,9 = 206.5, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM
(n = 4).***p < 0.001 compared with respective controls
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suggesting that DMG does provide benefits for some chil-
dren with autism The effectiveness of DMG combined
with a large dose of vitamin B6 (pyridoxal HCl) and mag-
nesium [43] has been revealed in young children with aut-
ism spectrum disorders although the mechanisms remain
unclear. Increasing evidence indicates that dysfunction of
NMDA receptors at excitatory synapses is associated with
autism spectrum disorders [23]. Treatment with the
NMDA receptor glycine site partial agonist D-cycloserine
[42] and GLYX-13 [27, 32] rescued the deficit in the ani-
mal models. Our findings demonstrated that DMG acts as
a partal agonist at glycine binding site of NMDA
Fig. 6 Effects of sarcosine or DMG on glutamate plus D-serine-evoked excitatory field potentials. The experimental protocol (a) and the frequency
and amplitude of NMDA receptor-mediated excitatory field potentials (b) after the application of D-serine alone, D-serine plus glutamate, and
co-application of sarcosine or DMG with glutamate plus D-serine were presented. The data were analyzed by one-way repeated measures ANOVA
(Frequency: F5,15 = 39.19.43, p < 0.001; Amplitude: F5,15 = 36.79, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM (n = 4). **p < 0.01,
***p < 0.01 compared with baseline. #p < 0.05, ###p < 0.001 compared with glutamate plus D-serine
Fig. 7 The docked poses of glycine (a), sarcosine (b), and DMG (c) with the NDMA receptor NR1 ligand-binding core (PDB ID: 1 PB7). Ligands
were presented as cyan sticks. Potential interacting residues were presented as green lines and labeled with their residue codes and indices.
Yellow dashed lines were presented for indicating potential hydrogen bonds (distance <3.5 Å)
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receptors, which might explain why it is beneficial to some
children with autism.
Conclusions
Our findings revealed that DMG might act as a partial
agonist at glycine binding site of NMDA receptors and
shed light on the mechanisms that might be responsible
for its putative use in autism and extend their potentials
in other central nervous system disorders including
schizophrenia and depression.
Additional files
Additional file 1: Figure S1. Characterization of DMG as a NMDA
receptor glycine binding site partial agonist. The experimental protocol
(AC) and the representative field potential recordings (BD) were shown.
Increased concentration of glycine from 10 to 100 μM could surmount
the inhibitory effect of DMG (100 μM). Elevated DMG concentration from
100 to 300 μM could attenuate the inhibitory effect of glycine binding
site antagonist 7-CK (1 μM). (PDF 282 kb)
Additional file 2: Figures S2. Effects of sarcosine or DMG combined
with NMDA and NMDA plus glycine on excitatory field potentials. The
effects of glutamate (100 μM) plus glycine (10 μM) and NMDA (30 μM)
plus glycine (10 μM) was compared first and blockade by MK-801. The
experimental protocol (A) and the representative EFPs recordings (B) were
shown as application of sarcosine (100 μM) or DMG (100 μM) combined
with NMDA or NMDA plus glycine. Sarcosine and DMG produced the same
effects when glutamate was replaced by NMDA. (PDF 251 kb)
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